| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | 0.0098 | 0.8 |
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | 0.0097 | 0.8 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.0094 | 0.8 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.021 | 0.8 |